Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Income towards Common Stockholders: 2014-2024

Historic Net Income towards Common Stockholders for Ultragenyx Pharmaceutical (RARE) over the last 11 years, with Dec 2024 value amounting to -$570.6 million.

  • Ultragenyx Pharmaceutical's Net Income towards Common Stockholders fell 35.12% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$581.2 million, marking a year-over-year decrease of 3.97%. This contributed to the annual value of -$570.6 million for FY2024, which is 5.95% up from last year.
  • As of FY2024, Ultragenyx Pharmaceutical's Net Income towards Common Stockholders stood at -$570.6 million, which was up 5.95% from -$606.6 million recorded in FY2023.
  • In the past 5 years, Ultragenyx Pharmaceutical's Net Income towards Common Stockholders registered a high of -$190.7 million during FY2020, and its lowest value of -$710.7 million during FY2022.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Net Income towards Common Stockholders value was -$606.6 million (recorded in 2023), while the average stood at -$629.3 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Net Income towards Common Stockholders skyrocketed by 52.69% in 2020, and later plummeted by 139.36% in 2021.
  • Ultragenyx Pharmaceutical's Net Income towards Common Stockholders (Yearly) stood at -$190.7 million in 2020, then slumped by 139.36% to -$456.4 million in 2021, then tumbled by 55.74% to -$710.7 million in 2022, then rose by 14.65% to -$606.6 million in 2023, then rose by 5.95% to -$570.6 million in 2024.